Medicine and Dentistry
Ovarian Cancer
100%
Endometrial Cancer
64%
Krukenberg Tumor
64%
Neoplasm
48%
Hysterectomy
37%
Gynecological Oncology
32%
Tumor Progression
30%
Malignant Neoplasm
29%
Overall Survival
21%
Sentinel Lymph Node
20%
Salpingectomy
19%
Surgery
19%
Small Interfering RNA
19%
Endometrium Carcinoma
19%
Recurrent Disease
18%
Minimally Invasive Surgery
17%
Tumor Cell
17%
Odds Ratio
17%
Platelet
17%
Progression Free Survival
16%
Surgeon
16%
Cytoreductive Surgery
15%
Ovarian Cancer Prevention
14%
Cancer Cell
14%
Disease
13%
Retroperitoneal Lymph Node Dissection
13%
Enhanced Recovery After Surgery
12%
Atypical Hyperplasia
11%
Lymph Node
11%
Health Care Cost
11%
Angiogenesis
11%
Adjuvant Therapy
11%
Bevacizumab
10%
Indocyanine Green
10%
Body Mass Index
10%
Cancer Growth
10%
Metastatic Carcinoma
10%
Cervical Cancer
10%
Venous Thromboembolism
10%
Clear Cell Carcinoma
10%
Hazard Ratio
10%
Pelvis
10%
Lymph Duct
9%
Oncologist
9%
Programmed Cell Death
9%
Vasculotropin
9%
Antiangiogenic Therapy
9%
Ectopic Pregnancy
8%
Squamous Cell Carcinoma
8%
Glycon
8%
Keyphrases
Ovarian Cancer
52%
Endometrial Cancer
34%
Tumor Growth
22%
Ovarian Carcinoma
21%
Small Interfering RNA (siRNA)
19%
Chemotherapy
18%
Clinical Cancer Research
17%
Tumor
16%
CD31
16%
Platelets
16%
Hysterectomy
15%
Endometrioid Endometrial Cancer
15%
Gynecologic Oncology
14%
Confidence Interval
13%
Overall Survival
13%
Epithelial Ovarian Cancer
13%
Focal Adhesion Kinase
12%
Sentinel Lymph Node Mapping
12%
Tumor Cells
12%
Bevacizumab
12%
Apologizing
11%
Progression-free Survival
11%
Serous Ovarian Carcinoma
11%
Stress Effect
10%
Adjuvant Therapy
10%
Cancer Growth
10%
Venous Thromboembolism
9%
Gene Silencing
9%
Salpingectomy
9%
Ovarian Cancer Screening
9%
Chitosan Nanoparticles
9%
Lymphovascular Invasion
8%
Resource Needs
8%
Interleukin-8
8%
Ovarian Clear Cell Carcinoma
8%
Notch Ligands
8%
EphB4
8%
Cancer Metastasis
8%
Early Endometrial Cancer
8%
Antiangiogenic Therapy
8%
Pembrolizumab
8%
July Effect
8%
Social Resources
8%
Metformin
8%
Indocyanine Green
8%
Targeted Gene
8%
EphA2
8%
FosB
8%
Atypical Hyperplasia
8%
Ovarian Cancer Cells
8%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
75%
Neoplasm
61%
Ovary Carcinoma
44%
Tumor Growth
38%
Small Interfering RNA
36%
Malignant Neoplasm
26%
Cancer Growth
17%
Vasculotropin
17%
Mouse
15%
Bevacizumab
14%
Metastasis
14%
Antiangiogenic Therapy
12%
Chemotherapy
12%
Endometrium Carcinoma
11%
Paclitaxel
9%
Focal Adhesion Kinase
9%
Chitosan Nanoparticle
9%
Interleukin 8
8%
Retrospective Study
8%
Pembrolizumab
8%
Clear Cell Carcinoma
8%
Adverse Outcome
8%
Thrombocytosis
8%
Noradrenalin
8%
Docetaxel
8%
Taxane
8%
Endometrium Cancer
7%
Disease
7%
Antiangiogenic
6%
Antitumor Activity
6%
Adrenergic Receptor
6%
Mouse Model
6%
Recurrent Disease
6%
Nanoparticle
5%
Cohort Study
5%
Phosphotransferase
5%
Venous Thromboembolism
5%
Carboplatin
5%
